Side-by-side earnings comparison across financial stats, AI summaries, management guidance, risks, quotes, and accountability signals.
Sun Pharma delivered a strong Q3 FY26 with consolidated revenue of INR 15,469 crore (+15.1% YoY) and EBITDA of INR 4,949 crore (+23.4% YoY), driven by broad-based growth in India (+16.2%) and emerging markets (+21.6%), partially offset by flat US sales.
Read Sunpharma analysis →Cipla's Q3 FY26 revenue was flat YoY at INR 7,074 crore, with EBITDA margin of 17.7% (down ~150-200bps vs internal expectations) due to lower generic revenues and elevated R&D spend (7% of sales, +37% YoY).
Read Cipla analysis →Sun Pharma delivered a strong Q3 FY26 with consolidated revenue of INR 15,469 crore (+15.1% YoY) and EBITDA of INR 4,949 crore (+23.4% YoY), driven by broad-based growth in India (+16.2%) and emerging markets (+21.6%), partially offset by flat US sales. EBITDA margin expanded to 31.9% on better product mix, while PAT grew 16% to INR 3,369 crore despite a higher tax rate. Management highlighted the upcoming launch of generic semaglutide in India as a key growth catalyst, with approvals received for both diabetes and weight management. However, US generic sales remain under pressure from competition and manufacturing compliance issues, and the company faces uncertainty from proposed US pricing reforms. The strong balance sheet (net cash $3.2B) provides M&A flexibility, though management remains disciplined.
Cipla's Q3 FY26 revenue was flat YoY at INR 7,074 crore, with EBITDA margin of 17.7% (down ~150-200bps vs internal expectations) due to lower generic revenues and elevated R&D spend (7% of sales, +37% YoY). PAT of INR 676 crore included a one-time INR 276 crore labor code charge. U.S. revenue fell to $167 million as Lenalidomide tapered and lanreotide supply was disrupted (partner Pharmathen paused production after FDA observations; resupply expected H1 FY27). India business grew 10% YoY, with respiratory crossing INR 5,000 crore. FY26 EBITDA margin guidance revised to ~21%. Key upcoming U.S. launches (4 respiratory, 4 peptide assets) are expected to offset revenue declines, but near-term headwinds persist. Risk: lanreotide disruption may extend beyond H1 FY27 if remediation is delayed.
India formulation sales grew 16.2% YoY to INR 49,986 million, driven by volume growth of 6.3% vs IPM volume growth of 1.2%.
Global innovative medicine sales grew 14.3% YoY to $423 million, including $55 million milestone income; ex-milestone growth was 13.2%.
US sales were marginally up 0.6% to $477 million, with growth in innovative medicines offset by lower generic sales due to competition.
Sun Pharma's market share in the Indian pharmaceutical market improved to 8.4% from 8.1% a year ago, maintaining the #1 position.
Sequential decline from ~$233M in Q2 FY26, driven by Lenalidomide taper and lanreotide supply disruption.
One India business delivered 10% YoY growth, with respiratory up 11% and chronic mix at 62.3%.
R&D investment at INR 4,194 crore, up 37.4% YoY, driven by pipeline development and API purchases.
Production paused after FDA 483 observations; resupply expected in H1 FY27, causing short-term disruption.
Sun Pharma plans to launch generic semaglutide in India on day one of patent expiry for both chronic weight management and type 2 diabetes, under brands NovelTreat and SemaTrinity.
Management guidance growthManagement indicated they will provide R&D spend guidance for the next fiscal year in the next quarter's call.
Management guidance otherThe phase 2b study for GL0034 in type 2 diabetes has started and is expected to complete within 12-18 months.
Management guidance otherManagement lowered FY26 EBITDA margin guidance to ~21% from earlier expectations, citing lower lanreotide and Lenalidomide impact.
Management guidance marginsPipeline includes generic Advair, two other large respiratory assets (likely Symbicort), and three peptide launches including generic Victoza.
Management guidance growthPartner Pharmathen paused production; resupply expected in H1 FY27, with alternate site evaluation underway.
Management guidance otherManagement will provide FY27 guidance after finalizing the annual operating plan.
Management guidance otherUS generic sales declined due to additional competition on certain products, and recovery depends on resolving manufacturing compliance issues at several sites.
high · management_commentaryCMS proposed pricing models could impact US revenues; management declined to share mitigation strategies, citing commercial sensitivity.
medium · analyst_questionEffective tax rate rose to ~25% from ~15% last year, dampening PAT growth relative to EBITDA growth; expected to remain in that range.
medium · data_observationManagement noted that milestone income of $55 million in Q3 may not recur in future quarters, potentially impacting revenue comparability.
low · management_commentaryPharmathen's manufacturing pause and 483 observations could delay resupply, impacting U.S. revenue.
high · management_commentaryRespiratory and peptide launches are critical to offset Lenalidomide decline; any delay or increased competition could pressure revenue.
high · analyst_questionR&D at 7% of revenue is above historical 5-6% range; management expects normalization but lumpy spending could continue.
medium · data_observationAnalyst questioned whether Cipla's agreement with Lilly restricts entry into semaglutide; management was evasive.
medium · analyst_questionOur focus is on finding a way to grow our business organically at a rate, so that we continue to be an attractive investment opportunity for shareholders. We would look at an acquisition only if we think that it can help us in terms of strengthening our long-term strategic capability.
What it really offers is balance between efficacy and tolerability. So Enloxit works three ways: It restores adaptive immunity, which is by binding to the PD-L1. It engages the innate immune system based on its active Fc domain that activates natural killer cells, and unlike the existing products, it preserves PD-L2 signaling.
We expect upcoming launches to help cushion the decline in Lenalidomide revenues and provide long-term growth.
The guidance will have to be revised because if we don't have lanreotide in one quarter, the numbers will be lower.
